

**STATE OF ILLINOIS
SECRETARY OF STATE
SECURITIES DEPARTMENT**

IN THE MATTER OF: RONALD HEINEMAN)
_____)

FILE NO. 0400470

AMENDED NOTICE OF HEARING

TO THE RESPONDENT: Ronald M. Heineman
(CRD #241924)
210 East 63rd Street
New York, NY 10021

Jerry M. Santangelo
Neal, Gerber & Eisenberg LLP
Two North LaSalle Street
Chicago, Illinois 60602-3801

You are hereby notified that pursuant to Section 11.E of the Illinois Securities Law of 1953 [815 ILCS 5] (the "Act") and 14Ill. Adm. Code 130, Subpart K, a public hearing will be held at 69 West Washington Street, Suite 1220, Chicago, Illinois 60602, on the 12th day of July, 2006, at the hour of 10:00 a.m., or as soon as possible thereafter, before James L. Kopecky, Esq. or such duly designated Hearing Officer of the Secretary of State.

Said hearing will be held to determine whether an Order shall be entered which would revoke Ronald M. Heineman's (the "Respondent"), registration as a salesperson in the State of Illinois and/or granting such other relief as may be authorized under the Act including but not limited to the imposition of a monetary fine in the maximum amount pursuant to Section 11.E of the Act, payable within ten (10) business days of the entry of the Order.

The grounds for such proposed action are as follows:

1. That on July 1, 2005 Respondent's Letter of Acceptance, Waiver and Consent was accepted by NASD's National Adjudicatory Council ("NAC") Review Subcommittee, or by the Office of Disciplinary Affairs on behalf of NAC which imposed the following sanctions:
 - a A suspension from association with any NASD member in all capacities for a period of thirty (30) days; and.

Amended Notice of Hearing

2

- b. A fine in the amount of Twenty-Two Thousand Five-Hundred (\$22,500) Dollars.
2. That NASD listed the following background information for Respondent: Respondent has been employed by Vertical Capital as its President, Registered Principal, and Registered Representative since May 29, 1997. Respondent was first registered with NASD in 1969 and became a General Securities Principal in 1971. Prior to Vertical Capital, Respondent was employed by or associated with other member firms.
 3. That the decision found:
 - a. Vertical Capital (BD #35909) is member of NASD located in New York, New York, and is approved by NASD as a broker-dealer, underwriter and selling group participant. From September 1995 through July 27, 2001, Vertical Capital was known as Security Capital Trading, Inc.
 - b. Morris was employed by Security Capital and Vertical Capital from January 2, 1998 until November 7, 2001 as a research analyst. He holds, and at all relevant times held, the Series 1, 7, and 63 licenses. Morris also holds a Masters of Business Administration degree from New York University, and the Chartered Financial Analyst designation.
 - c. Respondent is, and at all times relevant to the facts recounted in this AWC was, the President and Registered Principal of Vertical Capital and, prior to July 2001, Security Capital.
 - d. Morris covered emerging growth companies as a research analyst at Vertical Capital.
 - e. Among the research reports produced by Vertical Capital during Morris's tenures as a research analyst were reports concerning Tirex Corporation ("Tirex"), Asthma Disease Management, Inc. ("Asthma Disease"), and Neurotech Development Corporation ("Neurotech") (collectively, the "Reports"). The Tirex Report was issued on June 16, 1998. The Asthma Disease Report was issued on August 19, 1999. The Neurotech Report was issued on December 6, 2000.
 - f. Morris was the primary author of the Reports, Respondent, as the firm's President, reviewed and approved each Report. As part of his review of the Neurotech Report, Respondent discussed the

Amended Notice of Hearing

3

content of the Report with Morris and commented on the substance of the document prior to its release to Neurotech.

- g. Each of the Reports was delivered by Vertical Capital or Security Capital to the issuers. The issuers subsequently distributed the Reports to the investing public. The Neurotech Report was posted by Neurotech via hyperlink on Neurotech's website.
- h. Although the Neurotech Report did not contain a recommendation to buy, the Neurotech Report was optimistic about the financial prospects of Neurotech, in part based on the claim of Neurotech's management the Neurotech has secured lucrative contracts for the construction of health care facilities in Asia and South America. The Report stated that Neurotech's ability to reach the potential revenues and earnings was entirely dependent on the timely receipt of customers' deposits. Based on management's claims, the Report concluded that Neurotech had the "potential to reach a target price of \$6 in late 2004 or 2005." At the time of the Report, Neurotech shares were trading at approximately eleven cents per share. The claims by the Company that were recounted in the Report include the following:
 - i. That Neurotech, through its joint venture, had "just received its first deposits totaling \$16 million in financial instruments and assets from customers in China to begin \$77,000,000 in projects in that country."
 - ii. That Neurotech's joint venture had signed "\$675 million in new contracts in the last six months."
 - iii. That Neurotech "Currently has contracts to construct hospitals ships, rail-side hospitals and nursing homes in China, Indonesia and Venezuela "totaling \$1,360,000,000 and
 - iv. That Neurotech had "received a bank guarantee in the amount of \$100 million from its customers in Indonesia one year after the execution of a \$300,000,000 contract to build hospitals in that country," and that although that guarantee had not been monetized, it would be re-issued "with a longer-term maturity date and better projected financial stability."
- i. The Neurotech Report stated that validity of Neurotech's foreign contracts would be established only by the receipt of deposits. The Neurotech Report continued:

Financial Potential

The Company [Neurotech] has approximately \$2,000,000,000 in contracts. If Neurotech ramps up to a level where it can complete its backlog in 5 years it will be running at a rate of almost \$5000,000,000 per year within three years. Management is currently negotiating for additional contracts with several countries. If successful on all of these its backlog would grow to over \$6,000,000,000 by 2004. At this level it would expect revenues in excess of \$1,500,000,000 per year by 2006.

- j. *The Neurotech Report did not disclose, however, that in 1999, the SEC had disciplined Neurotech and its officers for misrepresenting to the investing public that Neurotech had obtained orders for hospitals and a guarantee from a Turkish bank, "when in fact there were neither orders nor guarantees." See SEC Release No. 7926. The Neurotech Report referred to the SEC enforcement action by slating that "[p]otential investors should...satisfy themselves as the company's legal proceedings and SEC matters. We understand from management that the latter is resolved and the former should not be a problem."*
- k. **Morris and Respondent knew of the SEC cease and desist order, including the nature of the allegations, prior to the release of the Neurotech Report to Neurotech.**
- l. **The Neurotech Report omitted material facts and qualifications concerning Neurotech when it failed to describe the nature of the SEC disciplinary action against Neurotech. In the light of the context of the material presented, the omission of information describing the SEC disciplinary action caused the basis for accepting Neurotech's statements of potential income offered in the Report, and it contained Neurotech's exaggerated and unwarranted statements regarding its financial prospects.**
- m. **The Tirez Report, the Asthma Disease Report, and the Neurotech Report were prepared pursuant to financial advisory agreements with each issuer. Part of the work performed by Vertical Capital or Security capital under the financial advisory agreements was preparation of the Tirez, Asthma Disease and Neurotech Reports. In all three instances, Morris, Respondent, and Security Capital received compensation from the issuers under the advisory agreements in the form of the issuers' restricted stock or warrants to purchase shares of the issuers' stock.**

Amended Notice of Hearing

5

- n. At the time the Tirez Report was completed, Morris and Respondent each held 663,743 restricted shares of Tirez stock, and Security Capital held warrants to purchase up to 2,000,000 shares of Tirez stock over two years at favorable prices. These shares and warrants were received as compensation for Security Capital, Morris and Respondents services under the financial advisory agreement with Tirez. The Tirez Report disclosed that Security Capital and "several of its employees" had received compensation for their services under the financial advisory agreement in the form of warrants to purchases shares, but the Report did not disclose the amount of restricted stock Security Capital and its employees had received.
- o. At the time that the Asthma Disease Report was completed, Morris and Respondent each held 1,430,000 restricted shares of Asthma Disease common stock which were received as compensation for their services under the financial advisory agreement with Asthma Disease. The Asthma Disease Report disclosed that Security Capital and its employees held shares of Asthma Disease stock that were received as compensation, but the Report did not disclose the amount of restricted stock Security Capital and its employees had received.
- p. At the time that Neurotech Report was completed, Vertical Capital held 512,224 restricted shares of Neurotech stock that had been received from Neurotech as compensation for their services under the advisory agreement with Neurotech. Likewise, Morris held 512,820 shares of Neurotech stock that had been received from Neurotech as compensation for the preparation of the Report. The Neurotech Report disclosed that Vertical Capital and its employees had received compensation, but did not disclose the amount of restricted stock Vertical Capital and its employees had received.
- q. During the time that the Tirez, Asthma Disease, and Neurotech Reports were researched and written, Vertical Capital and Respondent maintained written supervisory procedures that failed to address the standards and requirements that should be met in the preparation of a research report. None of the written procedures in place contain a description of the criteria used to evaluate research reports, apart from a general statement prohibiting exaggerated, promissory or false statements and a prohibition against "projections and predictions."

Amended Notice of Hearing

6

- r. Vertical Capital, through Respondent, failed to adequately supervise the preparation of the Reports' disclosures regarding the amount of consideration received by the firm, Respondent and Morris from the issuers. In addition, Vertical Capital, through Respondent, did not adequately supervise Morris's preparation of the Neurotech Report. For example, although Respondent knew of the nature of the SEC action against Neurotech. Respondent failed to ensure that the SEC action and its resolution were adequately described in the text of the report
 - s. By engaging in the course of conduct described above, Respondent violated NASD Conduct Rules 2110, 2210(d)(1)(A), 2210(d)(1)(B), and 2110 by violating Section 17(b) of the Securities Act of 1933. In addition, Respondent violated NASD Conduct Rules 3010(a), and 3010(b).
- 4. That Section 8.E(1)(j) of the Act provides, Inter alia, that the registration of salesperson may be revoked if the Secretary of State finds that such salesperson has been suspended by any self-regulatory organization registered under the Federal 1934 Act or the Federal 1974 Act arising from any fraudulent or deceptive act promulgated by the self-regulatory organization.
 - 5. That the NASDA is a self-regulatory organization as specified in Section 8.E(1)(j) of the Act.
 - 6. That by virtue of the foregoing the Respondents registration as a salesperson in the State of Illinois is subject to revocation pursuant to section 8.E.9(1)(j) of the Act.

You are further notified that you are required pursuant to Section 130.1104 of the Rules and Regulations (14 Ill. Adm. Code 130) (the "Rules"), to file an answer to the allegations outlined above within thirty (30) days of the receipt of this notice. A failure to file an answer within the prescribed time shall be construed as an admission of the allegations contained in the Notice of Hearing

Furthermore, you may be represented by legal counsel; may present evidence; may cross-examine witnesses and otherwise participate. A failure to so appear shall constitute default, unless any Respondent has upon due notice moved for and obtained a continuance.


Amended Notice of Hearing

7

A copy of the Rules under the Act pertaining to Hearings held by the Office of the Secretary of State, Securities Department, is included with this Notice.

Delivery of notice to the designated representative of any Respondent constitutes service upon such Respondent.

DATED: This 16th day of March 2006.


JESSE WHITE
Secretary of State
State of Illinois

Attorney for the Secretary of State:
Gregory J. Solberg
Office of the Secretary of State
Illinois Securities Department
69 West Washington Street, Suite 1220
Chicago, Illinois 60602
Telephone: (312) 793-3384

Hearing Officer
James L. Kopecky
321 North Clark Street
Suite 2200
Chicago, IL 60610
Telephone: (312) 527-3966